The Role of the Merrifield Solid Phase Method in the Discovery and Exploration of a New Class of Selective Vasopressin Hypotensive Agonists

No abstract is available for this paper.

• Publication year

  2007

• Venue

  International Journal of Peptide Research and Therapeutics

• Publication date

  2007-03-10

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1007/s10989-007-9089-9
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Design and synthesis of potent, highly selective vasopressin hypotensive agonists

  2006cited by this paper
• Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4.

  2004cited by this paper
• A comparison between haemodynamic effects of vasopressin analogues

  2004cited by this paper
• 124 years of publishing original and primary chemical research: 135,149 publications, 573,453 pages, and a century of excellence.

  2003cited by this paper
• JACS AT 125: PEPTIDES ON DEMANDBruce Merrifield's 1963 paper paved the way for automated synthesis of peptides and proteins

  2003cited by this paper
• A novel vasopressin peptide lowers blood pressure through decreases in cardiac output.

  2003cited by this paper
• Peptides: The Wave of the Future

  2001influential reference
• Design of More Potent, Radioiodinatable and Fluorescent Vasopressin Hypotensive Peptide Agonists

  2001cited by this paper
• Novel selective hypotensive vasopressin peptides: cardiovascular and structure-activity-relationship studies.

  2001cited by this paper
• Discovery and design of novel and selective vasopressin and oxytocin agonists and antagonists: the role of bioassays

  2000cited by this paper
• Discovery and design of novel vasopressin hypotensive peptide agonists.

  1999cited by this paper
• Synthesis and structure–activity investigation of novel vasopressin hypotensive peptide agonists

  1999cited by this paper
• Molecular pharmacology of AVP and OT receptors and therapeutic potential

  1999cited by this paper
• Discovery of Novel Selective Hypotensive Vasopressin Peptides

  1998cited by this paper
• Discovery of novel selective hypotensive vasopressin peptides that exhibit little or no functional interactions with known oxytocin/vasopressin receptors

  1998cited by this paper
• pA, A NEW SCALE FOR THE MEASUREMENT OF DRUG ANTAGONISM

  1997cited by this paper
• Position Three in Vasopressin Antagonist Tolerates Conformationally Restricted and Aromatic Amino Acid Substitutions: A Striking Contrast with Vasopressin Agonists

  1997cited by this paper
• Oxytocin: cellular and molecular approaches in medicine and research.

  1996influential reference
• Design, synthesis and some uses of receptor-specific agonists and antagonists of vasopressin and oxytocin.

  1993cited by this paper
• 1H-Pyrazole-1-carboxamidine hydrochloride an attractive reagent for guanylation of amines and its application to peptide synthesis

  1992influential reference
• Potent V2/V1a vasopressin antagonists with C-terminal ethylenediamine-linked retro-amino acids.

  1992cited by this paper
• Peripheral vasodilatation induced by a vasopressin analogue with selective V2-agonism in dogs.

  1989cited by this paper
• Vasopressin-mediated forearm vasodilation in normal humans. Evidence for a vascular vasopressin V2 receptor.

  1989cited by this paper
• Discovery, development, and some uses of vasopressin and oxytocin antagonists.

  1989cited by this paper
• Potent V2 vasopressin antagonists with structural changes at their C-terminals.

  1988cited by this paper
• C-terminal deletions in agonistic and antagonistic analogues of vasopressin that improve their specificities for antidiuretic (V2) and vasopressor (V1) receptors.

  1987cited by this paper
• No requirement of cyclic conformation of antagonists in binding to vasopressin receptors

  1987cited by this paper
• Solid phase synthesis

  1985cited by this paper
• Potent and selective antagonists of the antidiuretic responses to arginine-vasopressin based on modifications of [1-(beta-mercapto-beta,beta-pentamethylenepropionic acid),2-D-isoleucine,4- valine]arginine-vasopressin at position 4.

  1984cited by this paper
• Vasopressin Causes Endothelium‐Dependent Relaxations of the Canine Basilar Artery

  1984cited by this paper
• Design of more potent antagonists of the antidiuretic responses to arginine-vasopressin.

  1982cited by this paper
• A convenient method for O-alkylation of N-substituted tyrosines using a crown ether

  1981cited by this paper
• Synthetic antagonists of in vivo antidiuretic and vasopressor responses to arginine-vasopressin.

  1981cited by this paper
• [1-beta-Mercapto-beta,beta-cyclopentamethylenepropionic acid),2-(O-methyl)tyrosine ]argine-vasopressin and [1-beta-mercapto-beta,beta-cyclopentamethylenepropionic acid)]argine-vasopressine, two highly potent antagonists of the vasopressor response to arginine-vasopressin.

  1980cited by this paper
• Solid‐phase synthesis of somatostatin and glucagon‐selective analogs in gram quantities

  1978cited by this paper
• Solid-phase synthesis and pressor potency of (1-deamino-9-ethylenediamine)-lysine-vasopressin.

  1973cited by this paper
• Eine neue Methode zur Synthese von Peptiden: Aktivierung der Carboxylgruppe mit Dicyclohexylcarbodiimid unter Zusatz von 1‐Hydroxy‐benzotriazolen

  1970influential reference
• The purification of synthetic oxytocin and analogues by gel filtration on Sephadex G-15.

  1968cited by this paper
• Synthesis by the Merrifield method of a protected nonapeptide amide with the amino acid sequence of oxytocin.

  1968cited by this paper
• The synthesis of deamino-oxytocin by the solid phase method.

  1968cited by this paper
• Basic Pharmacological Properties of Synthetic Analogues and Homologues of the Neurohypophysial Hormones

  1968cited by this paper
• 6-Hemi-D-cystine-oxytocin, a diastereoisomer of the posterior pituitary hormone oxytocin.

  1965cited by this paper
• SOLID-PHASE PEPTIDE SYNTHESIS. 3. AN IMPROVED SYNTHESIS OF BRADYKININ.

  1964influential reference
• Solid phase peptide synthesis. I. the synthesis of a tetrapeptide

  1963cited by this paper
• A highly potent analogue of oxytocin, desamino-oxytocin.

  1962cited by this paper
• Effect of magnesium ion on the response of the rat uterus to neurohypophysial hormones and analogues.

  1960cited by this paper
• The Synthesis of Oxytocin1

  1954influential reference
• A SYNTHETIC PREPARATION POSSESSING BIOLOGICAL PROPERTIES ASSOCIATED WITH ARGININEVASOPRESSIN

  1954influential reference

• Impact of the Merrifield solid phase method on the design and synthesis of selective agonists and antagonists of oxytocin and vasopressin: A historical perspective

  2008cites this paper
• Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.

  2008cites this paper